Investors in VTGN Have Chance to Take Charge in Vistagen Therapeutics Fraud Case

VTGN Investors Can Take the Lead in Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Investors who are involved with Vistagen Therapeutics, Inc. (referred to as “Vistagen” or “the Company”) (NASDAQ: VTGN) have the opportunity to participate in a class action lawsuit by the Schall Law Firm, a national firm focused on shareholder rights litigation. This lawsuit targets violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 issued by the U.S. Securities and Exchange Commission.

Individuals who acquired the Company’s securities between April 1, 2024, and December 16, 2025 (known as the “Class Period”), are advised to reach out to the firm before March 16, 2026. Shareholders who suffered losses can join the case. The Schall Law Firm can be contacted through Brian Schall at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, or by phone at 310-301-3335 for a complimentary consultation. Alternatively, you can visit the company’s website at www.schallfirm.com or email them at [email protected].

It is essential to note that the class status for this case has not yet been certified. Until certification takes place, individuals are not represented by legal counsel. Investors who decide not to take action will remain absent class members.

During the Complaint, it is alleged that the Company distributed false and deceptive information to the market. Vistagen misled investors by indicating a high likelihood of Phase 3 success with its fasedienol drug candidate, creating an impression of positive outcomes from its PALISADE-2 trial. The Company failed to adequately address the risks associated with clinical studies. As a result, the Company’s public statements were deceptive and misleading throughout the class period. Once the truth regarding Vistagen emerged, investors experienced financial losses.

The Schall Law Firm has a global reach and specializes in securities class action lawsuits and shareholder rights litigation. It is important to be aware that this press release may be viewed as Attorney Advertising in certain jurisdictions.